Cargando…
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
OBJECTIVE: To evaluate the long-term effectiveness and tolerability of adalimumab in the treatment of psoriatic arthritis (PsA). METHODS: Patients with PsA who completed a 24-week, double-blind study of adalimumab versus placebo were eligible to enroll in an open-label extension study and receive ad...
Autores principales: | Mease, P J, Ory, P, Sharp, J T, Ritchlin, C T, Van den Bosch, F, Wellborne, F, Birbara, C, Thomson, G T D, Perdok, R J, Medich, J, Wong, R L, Gladman, D D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663711/ https://www.ncbi.nlm.nih.gov/pubmed/18684743 http://dx.doi.org/10.1136/ard.2008.092767 |
Ejemplares similares
-
Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
por: Gladman, Dafna D, et al.
Publicado: (2010) -
Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
por: Van den Bosch, F, et al.
Publicado: (2010) -
Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
por: Landewé, Robert, et al.
Publicado: (2019) -
Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
por: Mease, Philip J, et al.
Publicado: (2017) -
Treatment recommendations for psoriatic arthritis
por: Ritchlin, C T, et al.
Publicado: (2009)